Company Overview and News

135
The Zacks Analyst Blog Highlights: Autohome, Kingdee International Software Group, 58.com and Yanzhou Coal Mining

2018-04-17 zacks
Chicago, IL – April 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Autohome Inc. (ATHM - Free Report) , Kingdee International Software Group Company Limited (KGDEY - Free Report) , 58.com Inc. (WUBA - Free Report) and Yanzhou Coal Mining Company Ltd.
SGC K3GD STLD 1171 YZCHF APO.PRB APO.PRA WUBA ATB BAX MCHP APO NEE.PRI NEE.PRJ 0268 YZC ATHM AMCX NEE.PRC AMAT NEE.PRQ NEE.PRR FSLR NEE

14
4 Stocks to Buy as Chinese Economy Remains Resilient

2018-04-16 zacks
The world’s second-largest economy China has been growing by leaps and bounds for the past one year. Further, the Asian Development Bank stated in a report on Apr 11 that China would keep growing more than 6% in 2018 as well as 2019. The recent shift of focus from manufacturing to services has been pivotal in China’s economic growth story.
YZC 0268 K3GD 1171 YZCHF ATHM WUBA ATB UNF

15
The Zacks Analyst Blog Highlights: Autohome, Kingdee International Software Group, China Petroleum & Chemical, Yanzhou Coal Mining and PetroChina

2018-04-06 zacks
Chicago, IL – April 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Autohome Inc. (ATHM - Free Report) , Kingdee International Software Group Company Ltd. (KGDEY - Free Report) , China Petroleum & Chemical Corp.
LINDW K3GD STLD 1171 YZCHF SNP LHCG LCII CLAC ZBRA LSTR YZC 0268 CVGW SNP ATHM PATK CLACW CLACU SAIC FG LIND

14
China Manufacturing & Services PMI Improve: 5 Great Choices

2018-04-05 zacks
Even as China and the United States gear up for a trade war, China’s economy has been gaining traction. While factory activity touched its highest level since last December, services activity rebounded in March after hitting a four-month low in the prior month. Increase in steel production and removal of winter pollution restrictions contributed to these gains.
YZC 0268 SNP K3GD 1171 YZCHF ATHM SNP VIRT

50
Rio Exits Coal Business With $4 Billion of Deals in a Week - Bloomberg

2018-03-28 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
K3GD RIO BLT RIO 1171 YZCHF BHPBF AAL YZC RTPPF BHP UBS AAUKF RIO RTNTF BBL UBS.PRDCL BHP BHPLF NGLOY ULSGF

0
Shenhua Profit Rises to 5-Year High as China Curbs Boost Coal - Bloomberg

2018-03-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
1898 YACAF YZC K3GD 1171 YZCHF YAL 1088

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to YZC / Yanzhou Coal Mining Company Ltd. on message board site Silicon Investor.

YZC - Yanzhou Coal Mining - IPO priced at $15.75
CUSIP: 984846105